To evaluate the effects of combination ICI (subsequently referred to as ‘combi-ICI’) on the CNS, we used a clinically relevant cancer survivor model of melanoma: syngeneic mouse model (D4M-UV2 cells) and combination therapy of CTLA-4 and PD-1 blockade in mice. This evidence concerns the gene PDCD1 and melanoma.